Immuno-suppressive hydrogels enhance allogeneic MSC survival after transplantation in the injured brain

Alvarado‐Velez, Melissa; Enam, Syed Faaiz; Mehta, Nalini; Lyon, Johnathan G.; LaPlaca, Michelle C.; Bellamkonda, Ravi V.

doi:10.1016/j.biomaterials.2020.120419

Cited by 36 publications

(18 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Later on, more immunosuppressant types were developed. For instance, tofacitinib that inhibits the immune response through the janus kinase pathway, monoclonal antibodies (clazakizumab, tocilizumab) to inhibit inflammatory cytokines (such as interleukin (IL)-6), and multimeric Fas ligands (Adipogen) that can improve the survival of MSCs survival and support MSCs to induce T cells apoptosis (Figure 1) [23][24][25][26][27].…”

Section: Immunosuppressants To Prevent Allograft Rejection In Transplantationmentioning

confidence: 99%

“…Anti-IL-6 is locally released, as indicated by its local effects, such as less severe inflammation, nonoccurrence of matrix accumulation in draining lymph nodes, and unchanged systemic immune responses [64]. Another example, adding biological immunosuppressants, such as multimeric Fas ligand, in the hydrogel delivery system, improves MSCs survival by decreasing the CD8 + cytotoxic T cell population [26]. On the other hand, the microsphere system has been successfully developed to deliver an anti-TNF-α and IL-1-β for murine heart allografts [74].…”

Section: Biological Immunosuppressantmentioning

confidence: 99%

See 1 more Smart Citation

Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation

Anggelia

Huang

Cheng

et al. 2022

IJMS

View full text Add to dashboard Cite

An innovative immunosuppressant with a minimally invasive delivery system has emerged in the biomedical field. The application of biodegradable and biocompatible polymer forms, such as hydrogels, scaffolds, microspheres, and nanoparticles, in transplant recipients to control the release of immunosuppressants can minimize the risk of developing unfavorable conditions. In this review, we summarized several studies that have used implantable immunosuppressant delivery to release therapeutic agents to prolong allograft survival. We also compared their applications, efficacy, efficiency, and safety/side effects with conventional therapeutic-agent administration. Finally, challenges and the future prospective were discussed. Collectively, this review will help relevant readers understand the different approaches to prevent transplant rejection in a new era of therapeutic agent delivery.

show abstract

Section: Immunosuppressants To Prevent Allograft Rejection In Transplantationmentioning

confidence: 99%

Section: Biological Immunosuppressantmentioning

confidence: 99%

Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation

Anggelia

Huang

Cheng

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, data indicated augmented levels of neurotrophic factors which consequently improve TBI-associated deficits. Further investigation is warranted on the efficacy of immunosuppressive hydrogels to facilitate stem cell transplantation for neurodegenerative disorders 95 .…”

Section: Updated Preclinical and Clinical Studies Of The Utilization Of Msc Therapy On Tbimentioning

confidence: 99%

Mesenchymal Stem Cell-Induced Anti-Neuroinflammation Against Traumatic Brain Injury

et al. 2021

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a pervasive and damaging form of acquired brain injury (ABI). Acute, subacute, and chronic cell death processes, as a result of TBI, contribute to the disease progression and exacerbate outcomes. Extended neuroinflammation can worsen secondary degradation of brain function and structure. Mesenchymal stem cell transplantation has surfaced as a viable approach as a TBI therapeutic due to its immunomodulatory and regenerative features. This article examines the role of inflammation and cell death in ABI as well as the effectiveness of bone marrow-derived mesenchymal stem/stromal cell (BM-MSC) transplants as a treatment for TBI. Furthermore, we analyze new studies featuring transplanted BM-MSCs as a neurorestorative and anti-inflammatory therapy for TBI patients. Although clinical trials support BM-MSC transplants as a viable TBI treatment due to their promising regenerative characteristics, further investigation is imperative to uncover innovative brain repair pathways associated with cell-based therapy as stand-alone or as combination treatments.

show abstract

“…Furthermore, in the use of MSCs to treat traumatic brain injury, it has been proposed (54) that allogeneic mesenchymal stem cells can be actively rejected by the host immune response, mainly due to the cytotoxic CD8+ T cell-mediated response, which limits the therapeutic effect. Melissa et al (51) released Fas ligand (FasL) through agarose gel to induce the apoptosis of cytotoxic CD8 + T cells, thereby reducing immune rejection induced by allogeneic mesenchymal stem cells during transplantation.…”

Section: Increased Secretion Of Pro-inflammatory Cytokines and Activation Of Immunocytesmentioning

confidence: 99%

“…Melissa et al. ( 51 ) released Fas ligand (FasL) through agarose gel to induce the apoptosis of cytotoxic CD8 + T cells, thereby reducing immune rejection induced by allogeneic mesenchymal stem cells during transplantation.…”

Section: Immune Rejection Reaction Between Allogeneic and Autologous Mesenchymal Stem Cellsmentioning

confidence: 99%

The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous

et al. 2021

View full text Add to dashboard Cite

Intrauterine adhesion (IUA) is an endometrial fibrosis disease caused by repeated operations of the uterus and is a common cause of female infertility. In recent years, treatment using mesenchymal stem cells (MSCs) has been proposed by many researchers and is now widely used in clinics because of the low immunogenicity of MSCs. It is believed that allogeneic MSCs can be used to treat IUA because MSCs express only low levels of MHC class I molecules and no MHC class II or co-stimulatory molecules. However, many scholars still believe that the use of allogeneic MSCs to treat IUA may lead to immune rejection. Compared with allogeneic MSCs, autologous MSCs are safer, more ethical, and can better adapt to the body. Here, we review recently published articles on the immunomodulation of allogeneic and autologous MSCs in IUA therapy, with the aim of proving that the use of autologous MSCs can reduce the possibility of immune rejection in the treatment of IUAs.

show abstract

Immuno-suppressive hydrogels enhance allogeneic MSC survival after transplantation in the injured brain

Cited by 36 publications

References 54 publications

Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation

Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation

Mesenchymal Stem Cell-Induced Anti-Neuroinflammation Against Traumatic Brain Injury

The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous

Contact Info

Product

Resources

About